Capmatinib (Tabrecta) is a small-molecule inhibitor targeting the MET kinase, developed by Novartis and granted accelerated approval by the U.S. FDA in 2020. As a precision therapeutic, it has demonstrated significant efficacy in the field of non-small cell lung cancer (NSCLC).
Indications for Capmatinib (Tabrecta)
Core Treatment Population
Capmatinib is specifically indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have been confirmed to harbor mutations causing MET exon 14 skipping through an FDA-approved detection method.
Pre-administration Requirement
The status of MET exon 14 skipping mutation must be confirmed by molecular testing before initiating treatment with Capmatinib .
Dosage Forms and Properties of Capmatinib (Tabrecta)
Dosage Specifications
150mg Tablets: Light orange-brown, oval-shaped, film-coated tablets with beveled edges, no score lines. The imprint "DU" is pressed on one side, and the identifier "NVR" on the other side.
200mg Tablets: Yellow, with the same oval, film-coated design and beveled edges, no score lines. Marked with "LO" on one side and "NVR" on the other side.
Formulation Characteristics
Both dosage forms of the tablets adopt a special film-coating process, and their active core contains excipients such as microcrystalline cellulose and crospovidone.
The coating of the 150mg tablets contains colorants including iron oxide red and iron oxide yellow, while the 200mg tablets only contain iron oxide yellow.
Special note: Tablets must be swallowed whole; breaking, crushing, or chewing is prohibited.
Storage Methods for Capmatinib (Tabrecta)
Routine Storage Conditions
The original packaging of Capmatinib should be stored at 20-25℃ (68-77℉); short-term storage within the range of 15-30℃ (59-86℉) is permitted.
Moisture protection is essential; the desiccant inside the packaging must be kept in the bottle at all times.
Post-Opening Management
After the medicine bottle is first opened, the remaining medicine should be used up within 6 weeks; any unused medicine beyond this period must be discarded.
This strict requirement stems from the formulation's sensitivity to humidity—improper storage may lead to reduced efficacy.
